BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study. J Am Heart Assoc 2017;6:e004512. [PMID: 28096098 DOI: 10.1161/JAHA.116.004512] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, Eckardt L, Friede T, Haugaa KH, Hocini M, Lambiase PD, Marijon E, Merino JL, Peichl P, Priori SG, Reichlin T, Schulz-Menger J, Sticherling C, Tzeis S, Verstrael A, Volterrani M; ESC Scientific Document Group . 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022:ehac262. [PMID: 36017572 DOI: 10.1093/eurheartj/ehac262] [Reference Citation Analysis]
2 Hnat T, Veselka J, Honek J. Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy. ESC Heart Fail 2022. [PMID: 35437948 DOI: 10.1002/ehf2.13939] [Reference Citation Analysis]
3 Botto GL, Mantovani LG, Cortesi PA, De Ponti R, D'Onofrio A, Biffi M, Capucci A, Casu G, Notarstefano P, Scaglione M, Zanotto G, Boriani G; Italian Association of Arrhythmology and Cardiac Pacing (AIAC). The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: Economic and clinical implications from a health technology assessment perspective. Int J Cardiol 2022:S0167-5273(22)00483-1. [PMID: 35395289 DOI: 10.1016/j.ijcard.2022.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mcdonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JG, Coats AJ, Crespo-leiro MG, Farmakis D, Gilard M, Heyman S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CS, Lyon AR, Mcmurray JJ, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GM, Ruschitzka F, Skibelund AK. Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2021.11.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Mueller-leisse J, Brunn J, Zormpas C, Hohmann S, Hillmann HAK, Eiringhaus J, Bauersachs J, Veltmann C, Duncker D. Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology—A PROLONG-II Substudy. Sensors 2022;22:2037. [DOI: 10.3390/s22052037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 El-Battrawy I, Kovacs B, Dreher TC, Klein N, Rosenkaimer S, Röger S, Kuschyk J, Saguner AM, Kowitz J, Erath JW, Duru F, Akin I. Real life experience with the wearable cardioverter-defibrillator in an international multicenter Registry. Sci Rep 2022;12:3203. [PMID: 35217697 DOI: 10.1038/s41598-022-06007-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; Authors/Task Force Members:., ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. [PMID: 35083827 DOI: 10.1002/ejhf.2333] [Cited by in Crossref: 149] [Cited by in F6Publishing: 54] [Article Influence: 149.0] [Reference Citation Analysis]
8 Hillmann HAK, Hohmann S, Mueller-Leisse J, Zormpas C, Eiringhaus J, Bauersachs J, Veltmann C, Duncker D. Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter-Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction. Sensors (Basel) 2021;21:7798. [PMID: 34883802 DOI: 10.3390/s21237798] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726. [PMID: 34447992 DOI: 10.1093/eurheartj/ehab368] [Cited by in Crossref: 209] [Cited by in F6Publishing: 1012] [Article Influence: 209.0] [Reference Citation Analysis]
10 Mueller-Leisse J, Brunn J, Zormpas C, Hohmann S, Hillmann HAK, Eiringhaus J, Bauersachs J, Veltmann C, Duncker D. Extended follow-up after wearable cardioverter-defibrillator period: the PROLONG-II study. ESC Heart Fail 2021;8:5142-8. [PMID: 34480414 DOI: 10.1002/ehf2.13586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Blaschke F, Lacour P, Dang PL, Parwani AS, Hohendanner F, Walter T, Klingel K, Kühl U, Heinzel FR, Sherif M, Boldt LH, Pieske B, Tschöpe C. Wearable cardioverter-defibrillator: friend or foe in suspected myocarditis? ESC Heart Fail 2021;8:2591-6. [PMID: 33932118 DOI: 10.1002/ehf2.13340] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Tscholl V, Wielander D, Kelch F, Stroux A, Attanasio P, Tschöpe C, Landmesser U, Roser M, Huemer M, Heidecker B, Nagel P. Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis. ESC Heart Fail 2021;8:2428-37. [PMID: 33887109 DOI: 10.1002/ehf2.13353] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Koracevic G, Stojanovic M, Lovic D, Zdravkovic M, Sakac D. Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk. J Hum Hypertens 2021;35:564-76. [PMID: 33654234 DOI: 10.1038/s41371-021-00505-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Ashraf S, Ilyas S, Siddiqui F, Ando T, Shokr M, Panaich S, Briasoulis A, Afonso L, Khan M. Keeping up to date: a current review of wearable cardioverter defibrillator use. Acta Cardiol 2020;75:695-704. [PMID: 31687917 DOI: 10.1080/00015385.2019.1682337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Sinha AM, Bense J, Hohenforst-Schmidt W. The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital. J Interv Card Electrophysiol 2021;62:401-7. [PMID: 33200285 DOI: 10.1007/s10840-020-00898-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Dreher TC, El-Battrawy I, RÖger S, Rosenkaimer SL, Gerhards S, Kuschyk J, Borggrefe M, Akin I. Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for <90 Wear Days versus ≥90 Wear Days. In Vivo 2020;34:3601-10. [PMID: 33144474 DOI: 10.21873/invivo.12205] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Aidelsburger P, Seyed-Ghaemi J, Guinin C, Fach A. Effectiveness, efficacy, and safety of wearable cardioverter-defibrillators in the treatment of sudden cardiac arrest - Results from a health technology assessment. Int J Technol Assess Health Care 2020;:1-9. [PMID: 32600490 DOI: 10.1017/S0266462320000379] [Reference Citation Analysis]
18 . Considering the Need to Expand the Indications for Wearable Defibrillator Therapy. J Innov Card Rhythm Manag 2019;10:3751-60. [PMID: 32494421 DOI: 10.19102/icrm.2019.100707] [Reference Citation Analysis]
19 Veltmann C, Winter S, Duncker D, Jungbauer CG, Wäßnig NK, Geller JC, Erath JW, Goeing O, Perings C, Ulbrich M, Roser M, Husser D, Gansera LS, Soezener K, Malur FM, Block M, Fetsch T, Kutyifa V, Klein HU. Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry. Clin Res Cardiol 2021;110:102-13. [PMID: 32377784 DOI: 10.1007/s00392-020-01657-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
20 Rosenkaimer SL, El-Battrawy I, Dreher TC, Gerhards S, Röger S, Kuschyk J, Borggrefe M, Akin I. The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up. J Clin Med 2020;9:E893. [PMID: 32214048 DOI: 10.3390/jcm9030893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Mehta NA, Abdulsalam N, Kouides R, Ahmed H, Atif R, Shah A, Taylor S, Chuprun D, Huang D, Rao M. Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators. Clin Cardiol 2020;43:260-6. [PMID: 31860745 DOI: 10.1002/clc.23295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Klein N, Kuntz T, Dhein S. Avoiding implantation of a cardioverter-defibrillator by bridging with wearable defibrillator vest. Herz 2021;46:172-7. [PMID: 31555894 DOI: 10.1007/s00059-019-04854-6] [Reference Citation Analysis]
23 Duncker D, Veltmann C. Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure. Curr Heart Fail Rep 2018;15:368-75. [PMID: 30353399 DOI: 10.1007/s11897-018-0415-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kutyifa V, Vermilye K, Daimee UA, McNitt S, Klein H, Moss AJ. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death. Europace 2018;20:f225-32. [PMID: 29905788 DOI: 10.1093/europace/euy091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
25 Azibani F, Sliwa K. Peripartum Cardiomyopathy: an Update. Curr Heart Fail Rep 2018;15:297-306. [PMID: 30051292 DOI: 10.1007/s11897-018-0404-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
26 Masri A, Altibi AM, Erqou S, Zmaili MA, Saleh A, Al-Adham R, Ayoub K, Baghal M, Alkukhun L, Barakat AF, Jain S, Saba S, Adelstein E. Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Systematic Review and Meta-Analysis. JACC Clin Electrophysiol 2019;5:152-61. [PMID: 30784684 DOI: 10.1016/j.jacep.2018.11.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
27 Kovacs B, Reek S, Krasniqi N, Eriksson U, Duru F. Extended Use of the Wearable Cardioverter-Defibrillator: Which Patients Are Most Likely to Benefit? Cardiol Res Pract 2018;2018:7373610. [PMID: 30622822 DOI: 10.1155/2018/7373610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
28 Duncker D, Veltmann C. [Wearable defibrillator : Current evidence]. Herzschrittmacherther Elektrophysiol 2018;29:362-8. [PMID: 30357452 DOI: 10.1007/s00399-018-0601-z] [Reference Citation Analysis]
29 Lackermair K, Schuhmann CG, Kubieniec M, Riesinger LM, Klier I, Stocker TJ, Kääb S, Estner HL, Fichtner S. Impairment of Quality of Life among Patients with Wearable Cardioverter Defibrillator Therapy (LifeVest®): A Preliminary Study. Biomed Res Int 2018;2018:6028494. [PMID: 30050939 DOI: 10.1155/2018/6028494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
30 Nguyen E. Wearable Cardioverter-defibrillators for the Prevention of Sudden Cardiac Death: A Meta-analysis. J Innov Card Rhythm Manag. 2018;. [PMID: 32477809 DOI: 10.19102/icrm.2018.090506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Zylla MM, Hillmann HAK, Proctor T, Kieser M, Scholz E, Zitron E, Katus HA, Thomas D. Use of the wearable cardioverter-defibrillator (WCD) and WCD-based remote rhythm monitoring in a real-life patient cohort. Heart Vessels 2018;33:1390-402. [PMID: 29721674 DOI: 10.1007/s00380-018-1181-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
32 Röger S, Rosenkaimer SL, Hohneck A, Lang S, El-Battrawy I, Rudic B, Tülümen E, Stach K, Kuschyk J, Akin I, Borggrefe M. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting. BMC Cardiovasc Disord 2018;18:52. [PMID: 29544442 DOI: 10.1186/s12872-018-0790-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
33 Duncker D, Bauersachs J, Veltmann C. [Ventricular arrhythmias : What has been confirmed in therapy?]. Internist (Berl) 2017;58:1272-80. [PMID: 29071387 DOI: 10.1007/s00108-017-0341-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Duncker D, Michalski R, Müller-Leisse J, Zormpas C, König T, Veltmann C. [Device-based remote monitoring : Current evidence]. Herzschrittmacherther Elektrophysiol 2017;28:268-78. [PMID: 28812129 DOI: 10.1007/s00399-017-0521-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study. Clin Cardiol 2017;40:586-90. [PMID: 28333373 DOI: 10.1002/clc.22706] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
36 Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas CA, Pfister R, Thomas D, Fürnkranz A, Andrié RP, Napp A, Schmitt J, Karolyi L, Wakili R, Hilfiker-Kleiner D, Bauersachs J, Veltmann C. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol 2017;106:582-9. [PMID: 28275862 DOI: 10.1007/s00392-017-1090-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]